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CYTOKINES play an important role in the development and
persistence of the inflammatory lesions seen in Crohn’s
disease and ulcerative colitis. This review discusses the
current thinking of the role of cytokines in chronic
intestinal inflammation including the involvement of
immunoregulatory cytokines within the Thl and Th2
subsets.
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Introduction
Cytokines are powerful peptide molecules
secreted by a number of different cell lineages,
including cells of the immune system. Although
originally thought to be highly specific in their
actions, numerous studies over the past 5 years have
demonstrated a large amount of pleiotropism and
redundancy within the cytokine network. There-
fore, caution should be applied when evaluating the
role of these molecules in various inflammatory
disorders, whether of established or unknown
aetiology.
Crohn’s disease (CD) and ulcerative colitis (UC)
are both good examples of chronic inflammatory
disease of unknown aetiology.
2 CD can affect any
part of the intestine from mouth to anus, with the
inflammation often being transmural and the
infiltrate characterized by macrophages and lymph-
ocytes predominantly. The inflammatory process
in UC is confined to the mucosa and superficial
submucosa of the large bowel. The inflammatory
infiltrate comprises neutrophils and lymphocytes, as
well as other constituents of both acute and chronic
inflammation.
The study of these two diseases has been
hampered by the lack of a good animal model,
although the recent progress with transgenic and
knockout animals4-6 may prove useful. The
investigation of cytokines has been carried out at
great pace, but possibly at the expense of clarity and
uniformity of method. The aim of this review is to
clarify our current understanding of cytokines in
chronic intestinal inflammation and establish
whether current work is heading in the right
direction.
Animal Models
The use of animal models for inflammatory
bowel disease (IBD) initially relied on some form
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of chemically induced injury to the intestine. This
sets up an acute response, without always
producing the more typical chronic relapsing and
remitting form of inflammation seen in UC and
CD. However, some of these studies have been
useful in studying the role of cytokines. Gurbindo
et aL 8 have used the TNBS-induced colitis model in
rats to assess interleukin 2 (IL2) activity of lamina
propria mononuclear cells (LPMC) in the inflamed
colon. The LPMC isolated from animals with acute
colitis showed significantly less IL2 activity when
compared with animals with chronic or resolved
disease. In addition, LPMC from animals with acute
disease responded poorly to mitogen stimulation
(concanavalin A, 4 g/ml) when compared with the
other two groups. This poor response may be
secondary to preactivation in vivo, leaving the cells
refractory to further stimulation. There may also be
increased uptake of IL2 by a greater number of
immune cells bearing IL2 receptors on the cell
surface. Expression of these receptors and other
activation antigens goes up in the acute phase of
the disease in humans.9’1 Finally, the differences
observed may be a reflection of different lympho-
cyte subsets occupying the gut mucosa at the
various stages of the colitis model, and in turn,
these subsets may produce differing cytokine
profiles. This point has not been addressed as yet.
Using embryonic stem cell technology, a number
of groups have developed mouse mutants specific-
ally deficient in a given cytokine, thus allowing a
closer look at the role of that molecule in vivo.
Disruption of the IL2 gene resulted in the
development of a UC-like disease in mice,
4 while an
interleukin 10 (ILl0) knockout’ mouse developed
a chronic enterocolitis, The immunological per-
turbation found in the IL2-deficient animal strongly
mirrors that found in UC with high numbers of
activated T and B cells in the colonic mucosa, a
reduction in y8TCR+ cells, increased IgG1 and
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autoantibody levels, and the aberrant expression of
MHC class 2 molecules.
11-1s No pathogenic agent
could be isolated from these animals and the disease
did not develop in those kept under germ-free
conditions, thus implying that the inflammatory
responses were set off by either non-pathogenic
microbial flora or other luminal antigens.
The ILl0 mutant mice developed a chronic
enterocolitis involving the entire intestine, but with
duodenum, proximal jejunum, and proximal colon
most severely aected. However, there was normal
B and T cell development together with a normal
antibody response to various protein antigens.
Analysis of the immune response to a standard
nematode infection, however, showed a very much
higher y-interferon (2-IFN) response in mutants
compared with controls, thus indicating that
although ILl0 is not required for the Th2 response,
it plays an important role in controlling the Thl
response.
16 As with the IL2 model, no pathogen
could be isolated from diseased mice, and those kept
under strict specific pathogen-free conditions
suffered only a limited colitis affecting the proximal
colon. Other immunoregulatory abnormalities of
interest to IBD included increased class 2 expression
in the colon, and a 20-fold increase in tumour
necrosis factor (TNF0) and interleukin 6 (IL6)
production by spleen cells from mutant mice
activated with lipopolysaccharide (LPS) compared
with controls.
The implications from these studies are that both
Thl and Th2 subsets are essential in maintaining
immunological tolerance within the intestinal
mucosa.
Cytokines as Measures of Disease
Activity
There is now good evidence to suggest that
lymphocytes and macrophages within the inflam-
matory infiltrate of both UC and CD are in a
state of increased activation. They may express a
number of activation-associated antigens including
the 4F2 antigen,
9 the transferrin receptor,
1 and the
interleukin 2 receptor (IL2R),l’v all examples of
early antigens. Activated immune cells are capable
of producing a number of different cytokines
18
which may then contribute to the inflammatory
response. This may result in resolution or in
continuing tissue damage, the latter creating an
environment for the development of chronic
disease. Therefore, careful analysis of these
cytokines may be useful in establishing the nature
and activity of the disease, and in determining
whether they have a role in pathogenesis.
A number of different techniques have been used
to measure cytokines both in the peripheral blood
(PB) and at the mucosal level in patients with
inflammatory bowel disease (IBD). These have
included radio-immunoassays, ELISAs and bio-
assays (using specific cytokine-dependent cell
lines)
19-21 for estimation of protein levels, and either
Northern blots
22 or reverse transcripti0n-PCR
(polymerase chain reaction)
23 for cytokine message.
In addition, some groups have looked at isolated
cells taken from resection specimens, whilst others
have used pinch biopsies obtained at colonoscopy.
The differences in approach to investigation of these
diseases has naturally led to difficulties in comparing
results.
Interleukin 1 (IL1), IL6 and TNF are often
referred to as monokines as they are predominantly
secreted by activated monocytes. They have a wide
range of biological functions.24-26 Interleukin 8 is a
potent neutrophil chemoattractant and is also
produced by activated monocytes.
2v Increased
concentrations of all four of these molecules have
been found in active UC and CD, implying that they
have a role in the development of the inflammatory
mucosal lesion.
IL1 is a potent activator of both T and B cells,
it induces synthesis of acute phase proteins (via IL6)
and acts as an endogenous pyrogen. Biopsies taken
from patients with active CD and UC showed
higher levels of IL1 compared with healthy
controls, using a bioassay. In addition, the increased
production could be inhibited in a dose-dependent
fashion by prednisolone.
28 However, the use of
biopsies in tissue culture followed by homogeniza-
tion as in this study gives an absolute value for the
cytokine and not a ’per cell’ estimate. In addition,
it does not establish the source of this powerful
mediator. Other studies, however, have tried to
address some of these criticisms. Isolated mucosal
mononuclear cells taken from active IBD showed
significantly greater ILl fl production for both CD
and UC when compared with cells taken from
normal bowel.
29 This increase appeared to be on a
per cell basis as there was no significant difference
in the percentage of macrophages present in the
isolated cell population from inflamed mucosa
(median 14.5%) compared with normal mucosa
(median 13%). When the mononuclear cell popula-
tion was depleted of macrophages, the IL1/ activity
was appreciably reduced.
In more recent studies, further attempts have
been made to localize the site of IL1 production.
Using the isolated LPMC model, significantly
greater levels of both ILlo and IL1/ were found
in IBD patients at the mRNA and protein levels.
Enterocytes isolated from the same resection
specimens showed no ILl activity.
3 In situ
hybridization studies in the human shows message
for ILlfl in subepithelial macrophages,
31 but in
the rat acetic acid model of colitis the signal is found
predominantly in enterocytes.
32
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These results provide good evidence to suggest
that ILlfl production is increased in active CD and
UC. The main, if not the only source, is likely to
be tissue macrophages infiltrating from the PB.
IL6 is another pleiotropic cytokine which can be
secreted by a number of cell types including
activated T cells, B cells, fibroblasts, endothelium
and mesangial cells,
3 as well as monocytes. It
promotes terminal differentiation of B cells into
antibody-producing plasma cells,
34 induction of the
acute phase response by hepatocytes
3s and is an
important co-stimulatory molecule for T cells.36 Its
role has been investigated recently in various
chronic inflammatory disorders including rheuma-
toid arthritis,
3: Kawasaki disease
3 and in IBD.
39 It
has also been assessed as an early marker of the
acute phase response in patients with severe burns,
sepsis and acute pancreatitis.
4-42
Serum and mucosal concentrations of IL6 are
significantly higher in active CD and UC, compared
with inactive disease and normal controls.
39 The
positive rates in the serum ELISA assay were far
higher for active CD (18/20 90%) compared with
active UC (14/34 41.2%). Measurement of plasma
IL6 supported this difference with the median value
for active CD (32.5 pg/ml) being significantly
higher than active UC (12.5 pg/ml).
43 Correlation
with other markers of disease activity, however, is
variable. Of those studies that have applied statistics
to their results, good correlation with CDAI, ESR,
CRP and platelet count was only found in those
patients with mixed small and large bowel disease.43
In another recent study, no correlation was found
between IL6 and clinical indices. However, all the
acute phase proteins correlated with these indices.44
An explanation for these results may be the very
short half-life of IL6 in the PB (<5 min), when
compared with serum proteins (several days).
In addition, patients with active IBD are likely to
be on steroids, which have been shown to sup-
press IL6 synthesis by mononuclear cells in ldtro.
4s
Finally, the IL6 produced in the mucosa may be
rapidly cleared as it passes through the liver, thus
giving rise to lower values in the peripheral circu-
lation.
Further detailed investigation of IL6 protein and
mRNA has yielded interesting results. In a study of
mRNA levels using PCR, IL6 was found to be
significantly higher in active disease.
46 Using the
isolated LPMC model, similar results were recorded
but in addition, the amount of IL6 protein secreted
by cells from uninvolved UC mucosa was
significantly higher than that of CD.
19 This
difference was not seen for TNF or IL1/. When
the LPMC were depleted of macrophages, there was
a marked decrease in TNF secretion, but only a
slight decrease in ILlfl, and no change in IL6. These
depletion studies are supported by immuno-
histochemistry which shows plenty of IL6 in
mucosal T and B cells, as well as in macrophages.
46
There is no doubt that higher concentrations of
IL6 are found in active IBD, contributing to
inflammation, antibody production and the acute
phase response. But why are plasma and serum
concentrations significantly higher in CD if large
amounts of this cytokine are being produced by
uninvolved UC mucosa and not CD mucosa? There
are two possible explanations. Firstly, the isolation
technique may push the cells into a heightened state
of activation, and/or secondly, there may be a
greater contribution of IL6 from PB cells in CD.
Apart from its role in cachexia and endotoxic
shock, TNFa has a number of important
immunomodulatory effects including increased
expression of adhesion molecules,47’48 activation and
degranulation of granulocytes and macrophages,49’s
increases in endothelial and epithelial permeability,
and enhanced epithelial cell proliferation,
sl Unlike
the other monokines, TNF secretion remains more
tightly controlled in active IBD. Although
concentrations were significantly higher in active
disease compared with both inactive and normal
control groups in the LPMC model,
19 spontaneous
secretion was far lower than ILl fl and IL6, and the
response to stimulation with poke weed mitogen
(PWM) far greater. In studies of TNF mRNA,
no significant differences have been found between
disease and control groups. 46’52 Ill situ hybridization
localized message to macrophages deep in the
lamina propria,
31 which correlates well with
macrophage depletion studies (see above). Taken
together, these results suggest that there is tight
control of TNFo expression within the intestinal
mucosa at the translational stage. The differences in
expression compared with IL1 and IL6, and the
overlap in immunological effects, make it tempting
to suggest that this cytokine plays a far less
prominent role in IBD than its fellow monokines.
Further parallel studies of message and protein will
be essential to confirm or refute this.
Preliminary reports of increased IL8 expression
in IBD suggest that it is specific for active UC, at
both mRNA
s2 and protein levels, s3 However, the
method of quantification used in both these studies
was inadequate and a definitive study is awaited. A
rise in IL8 within the mucosa would be expected
in view of nature of the infiltrate, as well as the
ability of other cytokines such as IL1/ and TNF to
stimulate secretion of IL8 by various cell types,
s4
The colony-stimulating factors (CSF) form a
separate group of cytokines which play an
important role in both granulocyte and macrophage
proliferation, maturation and activation, ss For this
reason and presumably because a large part of the
inflammatory cell infiltrate is made up of these cells,
their role in IBD has been investigated using the
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isolated LPMC model, s6 Cells taken from inflamed
mucosa produced significantly more CSF, particu-
larly of the macrophage-derived G-CSF, when
compared with cells isolated from normal bowel.
In contrast, levels of interleukin 3 (IL3) and
GM-CSF were decreased compared with controls.
The results were similar for both constitutive
expression and following PHA stimulation. They
applied to both forms of IBD, and were confirmed
by slot-blot analysis of the respective mRNAs.
Distribution of cell types within the LPMC
population was assessed by cytospins and fluores-
cence analysis. There were no significant differences
between disease and control groups, apart from the
number of activated T cells, which as expected, was
much higher in the IBD group (using IL2R and
TFR expression).
The increased concentration of G-CSF correlates
with the greater number of activated immune ceils
in diseased mucosa. It is likely to contribute to
neutrophil and macrophage chemotaxis and activa-
tion, and thus perpetuate mucosal inflammation and
damage. Therefore, it may represent another marker
of disease activity but is unlikely to be related to
disease pathogenesis. The differences observed
between G-CSF, GM-CSF and IL3 production may
simply reflect the cell types being recruited into the
mucosa from PB, and subsequently changes in the
activity of other immunoregulatory cytokines that
control CSF production such as IL2.
Cytokines and Disease
Pathogenesis: The Role of Thl and
Th2 Subsets
The division of CD4+ T cells into Thl and Th2
subsets depending on their lymphokine secretion
patterns was first described in a murine model, sv
Subsequently, a similar model has been considered
for the human CD4+ T cell population, with the
two subsets having reciprocal effects on each
other, s8 Supporting evidence for this in vivo comes
from the study of infections which generate a
spectrum ofimmune responses in their hosts. These
include leprosy and leishmaniasis,s9’6 Analysis of
cytokine profiles in patients with different forms of
the same disease revealed that each subset was
associated with a specific immune response, thus
generating its own disease phenotype. Therefore, in
patients with tuberculoid leprosy, the Thl subset
(IL2 and y-IFN) predominates giving rise to a
cellular immune response and eradication of the
organism. In the lepromatous form, the Th2 subset
(IL4, IL5 and ILl0) predominates stimulating a
humoral response and persistence of infection, s9
However, predominance of Th2 cells is not always
associated with susceptibility. In certain situations,
a dominant Th2 response is required to keep an
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inappropriate and potentially immunopathologic
Thl response in check.
61
The role of these immunomodulatory cytokines
in IBD has generated much interest recently,
particularly with the development of spontaneous
intestinal inflammation in the IL2 and ILl0
’knockout mice’ (see above). At present, there is
some disagreement over the concentrations of IL2
in active IBD with both increases and decreases
being recorded. One obvious explanation for this
is the difference in materials and methods used. IL2
has been extensively studied in the isolated LPMC
model,21’22’62’63 with consistently reduced levels
found in cells taken from inflamed mucosa
compared with normal or uninvolved bowel. The
low IL2 protein and mRNA levels are attributed to
a loss of CD4+ IL2-producing intestinal T cells. 63
There is one exception to these findings using the
same model, with no significant differences in IL2
production between any of the groups.
64 In all these
studies, the authors insist that the type of therapy
(e.g. corticosteroids) does not appear to influence
IL2 levels. However, it is well-established that
corticosteroids inhibit IL2 mRNA expression
6s and
5-aminosalicylic acid also appears to inhibit
secretion of this cytokine at concentrations well
within the faecal fluid therapeutic range of 3 to
20 mM. 64
The study of IL2R expression
66 suggests a
reciprocal relationship with its ligand. Receptor
levels are increased in CD and unchanged in UC,
whereas IL2 levels measured by the same group
have always been reduced for both diseases. Most
of the receptor activity is within the T cell
compartment, and coexpression of o and fl chains
is likely in view of the large amounts of mRNA
found for both. Whether the IL2 deficiency is a
primary phenomenon, is related to the cell isolation
technique, or to greater binding and internalization
by a larger number of receptors is yet to be
established.
Using a mixed cell population within colono-
scopic biopsies, and a quantitative PCR technique,
IL2 mRNA expression was found to be significantly
higher in active CD compared with active UC and
normal controls.
23 The presence of an increased
number of immune cells within the IBD biopsies
was not controlled for; analysis of CD36 mRNA
by PCR may have been a suitable internal standard
to correct for this. A similar criticism may be
levelled at an earlier study of IL2 protein using
sonicated biopsies.
67
The other major component of the Thl subset is
y-IFN. This cytokine has a central role in
controlling development of the immune response,
with induction of a number of phagocyte and
lymphocyte functions68 and potent effects on the
expression of cell surface antigens including MHCRole of cytokines in inflammatory bowel disease
class 2. 69 Further evidence for this comes from the
multiple immunological defects seen in mice with a
disrupted y-IFN gene.
7 In isolated LPMC, y-IFN
concentrations were found to be significantly
reduced in cells taken from inflamed sites compared
with areas of uninflamed mucosa and normal
controls. 71 No -IFN was detected in unstimulated
cultures, but it could be induced equally by both
IL2 and PHA (1%). Depletion of the adherent cell
population generally resulted in a decrease in the
amount of 2-IFN detected. Analysis of T cells from
each group showed no significant differences either
in the absolute number of CD3+ cells or in the
subsets. Clinical disease activity and corticosteroid
treatment was said not to correlate with ),-IFN
concentrations.
Two other studies have found the opposite result,
with 7-IFN concentrations being higher in active
CD compared with controls.72’73 UC was not
assessed. However, on investigating the kinetics of
2-IFN production after stimulation of LPMC, Fais
et al.72 found that the CD LPMC peaked at 24 h and
then plateaued, whilst control cells produced
increasing amounts up to 72 h, when the experiment
was terminated. This observation, when taken
together with the other studies, suggests that T cells
within the inflamed mucosa may already have their
Thl cytokine genes ’turned on’ to near maximal
levels, and hence further increases in expression are
limited or impossible. The reduced concentrations
found in the first study cited could also be due to
alterations in cell type in the mucosa, a defect in
macrophage-T cell interaction or secondary to
reduced IL2 levels.TM However, it is difficult to
reconcile these results with the obvious increase in
class 2 expression in inflamed colon, the latter
thought to be predominantly mediated by ,-IFN.
An explanation for the limited or reduced Thl
response in active IBD may be found by studying
the activity of the Th2 subset, as has been done in
infectious diseases (see above). Work in this area is
limited, and has been presented in abstract form
only. IL4 is essential for the development of a full
Th2 response.
75 It has a number of functions
including activation of B cells,
76 control of lg
isotype switching,
77 and inhibitory effects on
79 80 macrophages.
78 Two studies using the LPMC
model show a reduced inhibitory response to
recombinant IL4 in IBD. In one, 2-IFN and IL2R
mRNA were measured as markers of Thl activity,
and in the other, macrophage activity was assessed
using mannose receptor expression and superoxide
generation. Assessment of IL4 mRNA and protein
at the mucosal level has not produced any consistent
results as yet.
Interleukin 10 has powerful inhibitory effects on
synthesis of Thl cytokines,
16 and can suppress
macrophage activation in vitro.
1 In view of the
extensive inflammation with T cell and macrophage
activation seen in IBD, investigation of its role is
essential but so far limited. In a small study using
colonoscopic biopsies and the RT-PCR method,
ILl0 mRNA was found to be higher in active UC
compared with active CD.
82 Taken together with
the IL2 data from the same author,
23 a theory of
CD being a Thl-driven disease and UC a
Th2-driven disease has been put forward. Using
similar methods, however, another study has found
ILl0 equally elevated in active CD and UC
(unpublished observations). At present, no major
conclusions can be made on the role of the Th2
cytokines in IBD.
Conclusions
Cytokines undoubtedly play an important role in
the development and persistence of the inflam-
matory lesions seen in CD and UC. There is now
good evidence to suggest that both IL1 and IL6 are
significantly elevated in active disease, and may be
used as markers of disease activity at the mucosal
level. The use of serum or plasma IL6 .as a marker
of activity, however, is limited in view of its very
short half-life. Control of TNF release appears to
be much tighter when compared with the other
monokines, and far more dependent on activated
macrophages as its source. Its contribution to the
inflammatory lesion is probably less important in
IBD.
The role of the immunoregulatory cytokines
within the Thl and Th2 subsets is complicated by
conflicting results, and a lack of data. The lower
concentrations of IL2 and 2-IFN in active disease
are consistent with the apparent loss of immuno-
logical tolerance seen in the IL2 knockout model.
Further study of differences between involved and
uninvolved mucosa in the same patient may help to
establish whether the Thl deficiency is merely a
reflection of infiltration of new, naive cells or a
predominance of primed, ’exhausted’ ceils. The
concept of a full Thl/Th2 profile in each patient is
attractive and has already yielded useful information
regarding the nature of the immune response in
the field of infectious disease. This approach may
not only elucidate whether these cytokines have a
primary role in the pathogenesis of IBD, but can
also help to establish whether there are fundamental
differences in the immune response in CD and UC.
References
1. Paul WE. Pleiotropy and redundancy: T cell derived lymphokines in the
immune response. Cell 1989; 57: 521-574.
2. Podolsky DK. Inflammatory bowel disease. New Engl J Med 1991; 325:
928-937.
3. Hammer RE, Maika SD, Richardson JA, Tang J-P, Tanrog JD. Spontaneous
inflammatory disease in transgenic rats expressing HLA-B27 and human
fl2M: animal model of HLA-B27-associated human disorders. Cell 1990;
63: 1099-1112.
Mediators of Inflammation-Vol 3.1994 7G. Radford-Smith and D. P. Jewell
4. Sadlack B, Merz H, Schoile H, Schimpl A, Feller AC, Horak I. Ulcerative
colitis-like disease in mice with disrupted interleukin-2 gene. Cell 1993; 75:
253-261.
5. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-
deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-274.
6. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK,
Tonegawa S. Spontaneous development of inflammatory bowel disease in T
cell receptor mutant mice. Cell 1993; 75: 275-282.
7. Stober W. Animal models of inflammatory bowel disease--an overview. Dig
Dis Sci 1985; 30: 3S-10S.
8. Gurbindo C, Russo P, Sabbah S, Lohoves M-J, Seidman E. Interleukin 2
activity of colonic lamina propria mononuclear cells in rat model of
experimental colitis. Gastroenterology 1993; 104: 964-972.
9. Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Boivirant M. Activation
of peripheral blood and intestinal lymphocytes in Crohn’s disease. In vivo
state of activation and in vitro response to stimulation defined by the
expression of early activation antigens. Gut 1987; 28: 745-753.
10. Schreiber S, MacDermott RP, Raedler A, Pinnau R, Bertovich MJ, Nash
GS. Increased activation of isolated lamina propria mononuclear cells in
inflammatory bowel disease. Gastroenterology 1991; 101: 1020-1030.
11. MacDermott RP, Nash GS, Bertovich MJ, Seiden MV, Bragdon MJ, Beale
MG. Alterations of IgM, IgG, and lgA synthesis and secretion by peripheral
blood and intestinal mononuclear cells from patients with ulcerative colitis
and Crohn’s disease. Gastroenterology 1981; 81: 844-852.
12. Kobayashi K, Asakura H, Hamada Y. T lymphocyte subpopulations and
immunoglobulin-containing cells in the colonic of ulcerative colitis:
morphometric and immunohistochemical study. J Clin Lab Immunol 1988;
25: 63-68.
13. Hibi T, Ohara M, Toda K, et al. In vitro anticolon antibody production by
mucosal peripheral blood lymphocytes from patients with ulcerative
colitis. Gut 1990; 31: 1371-1376.
14. Fukushima K, Masuda T, Ohtani H, et al. Immunohistochemical
characterization, distribution, and ultrastructure of lymphocytes bearing T
cell receptor y/a in inflammatory bowel disease. Gastroenterology 1991; 101:
670-678.
15. Mayer L, Eisenhardt D, Salomon P, Bauer W, Pious R, Piccinini L.
Expression of class 2 molecules intestinal epithelial cells in humans.
Gastroenterology 1991; 100: 3-12.
16. Fiorentino DF, Bond MW, Mossmann TR. Two types of T helper
cell. IV. Th2 clones secrete factor that inhibits cytokine production by Thl
clones. J Exp Med 1989; 170: 2081-2095.
17. Choy MY, Walker-Smith JA, Williams CB, MacDonald TT. Differential
expression of CD25 (interleukin-2 receptor) lamina propria T cells and
macrophages in the intestinal lesions in Crohn’s disease and ulcerative colitis.
Gut 1990; 321 1365-1370.
18. Balkmill FR, Burke F. The cytokine network. Immunol Today 1989; 10:
299-304.
19. Reinecker H, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott
R-P, Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL-6,
and IL-lfl by isolated lamina propria mononuclear cells from patients with
ulcerative colitis and Crohn’s disease. Clin Exp Immuno11993; 94: 174-181.
20. Gillis S, Smith KA. Long term culture of tumour-specific cytotoxic T cells.
Nature 1977; 268: 154-156.
21. Fiocchi C, Hilfiker ML, Youngman KR, Doerder NC, Finke JH. Interleukin
2 activity of human intestinal mononuclear cells. Decreased levels
in inflammatory bowel disease. Gastroenterology 1984; 86: 734-742.
22. Matsuura T, West G, Youngman KR, Klein S, Fiocchi C. Immune
activation genes in inflammatory bowel disease. Gastroenterology 1993; 104:
448-458.
23. Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased
interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn’s
disease but not ulcerative colitis. Gastroenterology 1992; 102: 1620-1627.
24. Dinarello C. lnterleukin and interleukin antagonism. Blood 1991; 77:
1627-1652.
25. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of
interleukin 6. Immunol Today 1990; 11: 443-449.
26. Vilcek J, Lee T. Tumour necrosis factor. New insights into the molecular
mechanisms of its actions. J Biol Chem 1991 266: 7313-7316.
27. Schroder J, Mrowietz U, Morita E, Christophers E. Purification and partial
biochemical characterization of human monocyte-derived, neutrophil-
activating peptide that lacks interleukin activity. J Immunol 1987; 139:
3473-3483.
28. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin
in inflammatory bowel disease--enhanced production during active disease.
Gut 1990; 31 686-689.
29. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin-1//by
mononuclear cells isolated from with active ulcerative colitis
Crohn’s disease. Gut 1989; 30: 835-838.
30. Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein
JS, Fiocchi C. Localization of intestinal interleukin activity and protein
and gene expression to lamina propria cells. Gastroenterology 1993; 104:
749-758.
31. Capello M, Keshav S, Prince C, Jewell DP, Gordon S. Detection ofmRNAs
for macrophage products in inflammatory bowel disease by in situ
hybridization. Gut 1992; 33: 1214-1219.
32. Radema SA, Van Deventer SJH, Cerami A. Interleukin 1// is expressed
predominantly by enterocytes in experimental colitis. Gastroenterology 1991;
100: 1180-1186.
33. Van Snick J. Interleukin 6: overview. Ann Rev Immuno11990; 8: 253-278.
34. Raynal MC, Lin Z, Hirano T, Mayer L, Kishimoto T, Chen-Kiang S.
Interleukin induces secretion of IgG1 by coordinated transcriptional
activation and differential mRNA accumulation. Proc Natl A cad Sci USA
1989; 86: 9024-9028.
35. Gauldie J, Richards C, Harmish D, Landsdorp P, Baumann H. Interferon
//2/B-cell stimulatory factor type 2 shares identity with monocyte-derived
hepatocyte-stimulating factor and regulates the major acute phase protein
response in liver cells. Proc NatlAcad Sd USA 1987; 84: 7251-7255.
36. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T.
IL6/BSF-2 functions killer helper factor in the in vitro induction of
cytotoxic T cells. J Immuno11988; 141 1543-1549.
37. Houssiau FA, Devogelaer JP, Damme JV, et al. Interleukin-6 in synovial
fluid and of patients with rheumatoid arthritis and other inflammatory
arthritides. A rth Rheum 1988; 31 784-788.
38. Ueno Y, Takano N, Kanegane H, et al. The acute phase nature of interleukin
6. Studies in Kawasaki disease and other febrile illnesses. Clin Exp Immunol
1989; 76: 337-342.
39. Mitsuyama K, Sata M, Tanikawa K. Significance of interleukin-6 in patients
with inflammatory bowel disease. Gastroenterologia Japonica 1991; 26: 20-28.
40. Nijsten MW, DeGroot ER, TenDuis HJ, Klesen HJ, Hack CE, Aarden LA.
Serum levels of interleukin 6 and acute phase responses (letter). Lancet 1987;
ii: 921.
41. Waage A, Brandtzaeg P, Halstensen A, Kievulf P, Espevik T. The complex
pattern of cytokines in from patients with meningococcal septic shock.
Association between interleukin-6, interleukin-1, and fatal outcome. J Exp
Med 1989; 169: 333-338.
42. Leser HG, Gross V, Scheibenbogen C, et al. Elevation of interleukin-6
concentration precedes acute-phase response and reflects severity in acute
pancreatitis. Gastroenterology 1991; 101: 782-785.
43. Lobo AJ, Evans SW, Jones SC, et al. Plasma interleukin-6 in inflammatory
bowel disease. Eur J Gastro Hep 1992; 4: 367-372.
44. Gross V, Andus T, Caesar J, Roth M, Sch61merich J. Evidence for
continuous stimulation of interleukin-6 production in Crohn’s disease.
Gastroenterology 1992; 102: 514-519.
45. Woloski BM, Smith EM, Meyer WJ, Fuller GM, Blalozk JE.
Corticotropin-releasing activity of monokines. Science 1985; 230: 1035-1037.
46. Stevens C, Walz G, Singaram C, et al. Tumour necrosis factor-,
interleukin-1//, and interleukin-6 expression in inflammatory bowel disease.
Dig Dis Sci 1992; 37: 818-826.
47. Bevilacqua MP, Pober JS, Mendrik DL, Cotran RS, Gimbrone MA Jr.
Identification of inducible endothelial leucocyte adhesion molecule. Proc
NatlA cad Sci USA 1987; 84: 9238-9242.
48. Pober JS, Lapierre LA, Stolpen AH, Brock TA, Springer TA. Activation
of cultured human endothelial cells by recombinant lymphotoxin:
comparison with tumour necrosis factor and interleukin species. J Immunol
1987; 138: 3319-3324.
49. Klebanoff Sj, Vadas MA, Harlan JM, et al. Stimulation of neutrophils by
tumour necrosis factor. J Immuno11986; 136: 4220-4225.
50. Hoffman M, Weinberg JB. Tumour necrosis factor- induces increased
hydrogen peroxide production and Fc receptor expression, but not increased
antigen expression by peritoneal macrophages. J Leukocyte Biol 1987; 42:
704-707.
51. Vidrich A, Anton P, Shanahan F. Cytokines modulate the growth of normal
colonic epithelia. Gastroenterology 1992; 102: A701.
52. Isaacs KL, Balfour Sartor R, Haskill S. Cytokine mesanger RNA profiles in
inflammatory bowel disease detected by polymerase chain reaction
amplification. Gastroenterology 1992; 103: 1587-1595.
53. Mahida YR, Coska M, Effenberger F, Kurlak L, Lindley I, Hawkey CJ.
Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active
ulcerative colitis. Clin Sci 1992; 82: 273-275.
54. Matsushima K, Morishita Y, Yoshimura T, et al. Molecular cloning of
human monocyte-derived neutrophil chemotactic factor (MDNCF) and the
induction of MDNCF mRNA by interleukin-1 and tumour necrosis factor.
J Exp Med 1988; 167: 1883-1893.
55. Clark SC, Kamen R. The human haemopoietic colony-stimulating factors.
Science 1987; 236: 1229-1237.
56. Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF. Enhanced
mucosal cytokine production in inflammatory bowel disease. Gastroenterology
1992; 102: 529-537.
57. Mosmann TR, Coffman RL. Thl and Th2 cells: different patterns of
lymphokine secretion lead to different functional properties. Ann Rev Immunol
1989; 7: 145-173.
58. Maggi E, Parronchi P, Maretti R, et al. Reciprocal regulatory effects of
IFN-gamma and IL-4 the in vitro development of human Thl and Th2
clones. J Immuno11992; 148: 2142-2147.
59. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses
to pathogens: cytokine profiles in leprosy lesions. Science 1991 254: 277-279.
60. Caceres-Dittmar G, Tapia FJ, Sanchez MA, et al. Determination of the
cytokine profile in American cutaneous leishmaniasis using the polymerase
chain reaction. Clin Exp Immunol 1993; 91: 500-505.
61. Urban JF, Madden KB, Svetic A, et al. The importance of the Th2 cytokines
in protective immunity to nematodes. Immunol Rev 1992; 127: 205-220.
62. Kusugami K, Youngman KR, West GA, Fiocchi C. Intestinal immune
8 Mediators of Inflammation. Vol 3.1994Role of cytokines in inflammatory bowel disease
reactivity to interleukin 2 differs among Crohn’s disease, ulcerative colitis,
and controls. Gastroenterology 1989; 97; 1-9.
63. Kusugami K, Matsuura T, West GA, Youngman KR, Rachmilewitz D,
Fiocchi C. Loss of interleukin-2-producing CD4+ T cells in inflammatory
bowel disease. Gastroenterology 1991 101: 1594-1605.
64. Pullman WE, Doe WF. IL-2 production by intestinal lamina propria cells
in normal inflamed and cancer-bearing colons. Clin Exp Immunol 1992; 88:
132-137.
65. Arya SK, Wong-Staal F, Gallo R. Dexamethasone-mediated inhibition of
human T cell growth factor and gamma-interferon messenger RNA.
J Immuno11984; 133: 273-276.
66. Matsuura T, West GA, Klein S, Ferraris L, Fiocchi C. Soluble interleukin
2 and CD8 and CD4 receptors in inflammatory bowel disease. Gastroenterology
1992; 102: 2006-2014.
67. Brynskov J, Tvede N, Andersen CB, Vilien M. Increased concentrations of
interleukin-lfl, interleukin-2, and soluble interleukin-2 receptors in
endoscopical mucosal biopsy specimens with active inflammatory bowel
disease. Gut 1992; 33: 55-58.
68. De Mayer, E, De Mayer-Guignard J. Production of INF-y by T cells and
modulation of T cells, B cell and NK activity by interferons. In: De Mayer
E, De Mayer-Guignard J, eds. Interferons and Other Regulatory Cytokines. New
York: John Wiley, 1988; 221-273.
69. Capobianchi MR, Ameglio F, Tosi R, Dolei A. Difference in the expression
and release of DR, BR and DQ molecules in human cells treated with
recombinant interferon gamma: comparison to other interferons. Hum
Immunol 1985; 13: 1-5.
70. Dalton DK, Pitts-Meeks S, Keshav S, Figari IS, Bradley A, Stewart TA.
Multiple defects of immune cell function in mice with disrupted interferon-y
genes. Science 1993; 259: 1739-1742.
71. Lieberman BY, Fiocchi C, Youngman KR, Sapatnekar WK, Proffitt MR.
Interferon production by human intestinal mucosal mononuclear cells.
Decreased levels in inflammatory bowel disease. Dig Dis Sci 1988; 33:
1297-1304.
72. Fais S, Capobianchi MR, Pallone F, Di Marco P, Boirivant M, Dianzani M,
Torsoli A. Spontaneous release of interferon by intestinal lamina propria
lymphocytes in Crohn’s disease. Kinetics of in vitro response to interferon
inducers. Gut 1991; 32: 403-407.
73. Sasaki T, Hiwatashi N, Yamazaki H, Noguchi M, Toyota T. The role of
inteferon in the pathogenesis of Crohn’s disease. Gastroenterologica Japonica
1992; 27: 29-36.
74. Kasahara T, Hooks J, Dougherty SF, Oppenheim JJ. Interleukin
2-mediated immune interferon (IFN-y) production by human T cells and T
cell subsets. J Immuno11983; 130: 1784-1789.
75. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G.
Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature
1993; 362: 245-247.
76. Yokota T, Otsuka T, Mosmann T, et al. Isolation and characterization of
human cDNA clone, homologous to B-cell stimulatory factor 1, that
expresses B-cell- and T-cell-stimulating activities. Proc NatlA cad Sci USA
1986; 83: 5894-5898.
77. Snapper CM, Finkelman FD, Paul WE. Differential regulation of IgG1 and
IgE synthesis by interleukin 4. J Exp Med 1988; 167: 183-196.
78. Essner R, Rhoades K, McBride WH, Morton DL, Economou" JS. IL-4
down-regulates IL-1 and TNF gene expression in human monocytes.
J Immuno11989; 142: 3857-3865.
79. Matsuura T, West GA, Klein JS, Levine AD, Kusugami K, Morise K,
Fiocchi C. Immune activation gene products resistant to IL-4 inhibitory
activity, in Crohn’s disease (CD). Gastroenterology 1993; 104: A739.
80. Schreiber S, Blum JS, Howaldt S, Berghaus D, Baldassano RN, Raedler A.
Deactivation of intestinal macrophages and induction of receptor
expression by interleukin 4: defective regulation in IBD. Gastroenterology
1993; 104: A776.
81. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A. IL-10
inhibits cytokine production by activated macrophages. J Immuno11991; 147:
381 5-3822.
82. Mullin GE, Vezza FR, Sampat A, et al. Abnormal IL-10 mRNA production
in the intestinal mucosal lesions of inflammatory bowel disease.
Gastroenterology 1993; 104: A751.
Received and accepted
30 November 1993
Mediators of Inflammation. Vol 3.1994 9